Rob Etherington, Clene Nanomedicine CEO

Clene claims its PhII MS tri­al, half its in­tend­ed size, cleared the pri­ma­ry goal. But can the biotech af­ford PhI­II?

Clene Nanomed­i­cine said its gold nanocrys­tal-based drug can­di­date, which failed an ALS tri­al last year, was bet­ter than place­bo in a mid-stage study of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.